The REMAP-CAP trial, which began investigating treatments for COVID-19 in March, has been trialling potential treatments in hospitalised patients with either moderate or severe COVID-19. On November 17th, the Data and Safety Monitoring Board (DSMB) informed the International Trial Steering Committee of results for lopinavir/ritonavir and tocilizumab in severe COVID-19.
Journalists dialled in to hear the researchers involved discuss these results, and what they mean for patients.
Prof Anthony Gordon, Professor of Anaesthesia and Critical Care, NIHR Research Professor, Imperial College London and UK Chief Investigator of the REMAP-CAP trial
Dr Lennie Derde, Intensive Care Consultant and European Coordinating Investigator of the REMAP-CAP trial
Mr Paul Mouncey, Head of Research, Intensive Care National Audit & Research Centre (ICNARC)
This Briefing was accompanied by an SMC Roundup of Comments.